Cases of Fen-Phen and SSRI-Related Lung Disorder Rise



Category: Fen Phen

More Info: Defective Drugs

In the fall of 1997, American Home Products Corporation, which became Wyeth in 2002, withdrew the drugs Pondimin (fenfluramine), and Redux (dexfenfluramine), which were prescribed together with phentermine for weight loss, in a combination called “fen-phen,” for short.

Fen-phen causes a life-threatening lung disorder known as primary pulmonary hypertension or PPH. According to the Pulmonary Hypertension Association, PPH is a rare blood vessel disorder of the lung in which the pressure in the pulmonary artery rises above normal levels and can become life-threatening.

As the blood is pumped through the arteries in the lungs, it receives oxygen; this oxygenated blood returns to the heart where it is then transported to the rest of the body through the aorta and other arteries. Changes to the pulmonary artery can cause the vessel to tighten, limiting the passage of blood, and increasing the pressure in the artery, according to the Lung Disorder website.

Phentermine was never FDA approved to be used with other drugs, rather the fen-phen drugs were approved to be used separately in the management of obesity for brief periods of time.

However, doctors prescribed the fen-phen combination to an estimated 6 million consumers in what the FDA refers to as “off label” use, meaning there were no studies submitted to the agency to substantiate the effectiveness or safety of the drugs when used together for any indication or for longer than a few weeks.

The two drugs were around a long time before they were used in the off-label combination. Phentermine was FDA approved in 1959 and fenfluramine in 1973. Fenfluramine had the side effect of making people sleepy, thus the goal of combining the drugs was to counter the sleepiness by adding phentermine, a mild stimulant.

On August 27, 1997, Dr Michael Friedman, acting Commissioner of the FDA at the time, was interviewed on PBS and blamed the off-label prescribing of the two drugs together for the PPH problem, saying that when the drugs were used in accordance with the approved label instructions, the condition was extremely rare.

“When these medications are used outside of those labeled indications,” he said in the interview, “at a higher dosage, for a longer period of time, or in combination with one another, then these side effects are seen more frequently.”

Medical experts now say that there can be a latency of ten or more years between the last date on which a patient uses fen-phen and when the first symptoms of PPH appear. “PPH is extremely rare,” the Pulmonary Association says, “occurring in about two persons per million population per year.”

According to the Lung Disorder educational information website, PPH is difficult to study because it is so rare. Of the estimated 300 cases diagnosed each year in the US, the majority occur in women between the ages of 21 and 40.

Eleven years ago, in 1996, the International Primary Pulmonary Hypertension Study reported that the use of the appetite suppressants in the fen-phen combination increased the risk of PPH to between 23 and 46 cases per million, and the disorder increased more than 20-fold when the drugs were used for longer than three months.

The FDA website reports that, within four years of developing PPH, about 40% of the patients die. Symptoms of the disorder include shortness of breath with minimal exertion, fatigue, dizzy spells, fainting, and chest pain.

Because PPH is normally so rare, it was not difficult to prove a link between PPH and the use of fen-phen. The first wrongful death lawsuit was filed in 1999, on behalf of the family of Mary Linnen, who took fen-phen for only 23 days before developing PPH. She lived less than a year after she was diagnosed and the jury awarded $29.2 million to the family, but the case was later settled for about half that amount.

The lawsuits currently filed against Wyeth allege that the drugmaker was fully aware that fen-phen was being prescribed off-label and profited with the off-label sales of Pondimin in the US, which rose from $3.7 million in 1993 to $150 million in 1996.

The lawsuits charge that the company knew of at least 41 reports of PPH in 1994, and by 1996, it knew about 71 cases, including 12 deaths, and yet failed to warn consumers and doctors about fen-phen’s association with the disorder.

Continue reading...

See the original article here: https://www.lawyersandsettlements.com/legal-news/pph_class_action/fen-phen-rise-00762.html


About TriMark Legal Funding

TriMark Legal Funding was founded in 2003 and is one of America's leading national lawsuit funding companies. TriMark provides pre-settlement funding and post-settlement funding, sometimes called 'lawsuit loans', to injured plaintiffs throughout the United States. We offer funding on hundreds of different types of legal claims including personal injury loans, employment litigation funding, work injury accident loans, workers compensation loans, mass tort litigation funding, and multidistrict litigation funding.

We also provide immediate inheritance advance funding for heirs and beneficiaries, as well as attorney funding and law firm financing for legal practices.

Personal Injury Lawsuits Mass Torts

Click here to see the original article.

Scroll to Top